Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.
Virios Therapeutics, Inc. (VIRI) is a clinical-stage biotechnology company advancing novel therapies for unmet medical needs through rigorous research and strategic collaborations. This page serves as your centralized source for official company announcements and developments.
Access timely updates on clinical trial progress, regulatory milestones, and partnership agreements. Investors and researchers will find essential information about therapeutic pipeline advancements, financial disclosures, and scientific publications. All content is verified through primary sources to ensure accuracy.
Key updates include trial phase results, intellectual property developments, and executive leadership announcements. Bookmark this page to stay informed about Virios Therapeutics' contributions to biopharmaceutical innovation without needing to track multiple channels.
Virios Therapeutics (Nasdaq: VIRI) has received initial feedback from the FDA regarding its Phase 3 program proposal for IMC-1, a combination treatment targeting fibromyalgia. The FDA considers the proposal acceptable, pending review of final toxicology program results. The proposed Phase 3 program includes two controlled clinical studies and a long-term safety trial. Final toxicology results will be submitted in May 2023, with further updates expected as the FDA review progresses. This program aims to address the significant unmet medical need in the fibromyalgia community, as no new treatments have been FDA-approved for this condition in over a decade.
Virios Therapeutics (Nasdaq: VIRI) reported its financial results for Q4 and full-year 2022. The company experienced a significant reduction in R&D expenses, totaling $1.3 million in Q4 2022, down from $2.9 million in Q4 2021. General and administrative expenses also fell to $0.8 million in Q4 2022 from $1.3 million in Q4 2021. The net loss for Q4 2022 stood at $2.0 million, or $0.11 per share, compared to a loss of $4.5 million, or $0.54 per share, a year earlier. For the full year 2022, the net loss was $12.2 million, down from $16.0 million in 2021. As of year-end, the company held $7.0 million in cash, with funding anticipated through mid-2024 for ongoing programs.
FAQ
What is the current stock price of Virios Therapeutics (VIRI)?
What is the market cap of Virios Therapeutics (VIRI)?
